Last updated: February 20, 2026
Entecavir is an antiviral medication used primarily for the treatment of chronic hepatitis B virus infections. Its manufacturing involves several specialized pharmaceutical suppliers capable of producing active pharmaceutical ingredients (APIs) and finished dosage forms under strict quality controls.
Major API and Finished Dosage Form Suppliers
1. API Suppliers
Global manufacturers supply entecavir APIs, primarily catering to generic pharmaceutical companies and branded drug producers.
| Supplier Name |
Location |
API Capacity (kg/year) |
Certification & Standards |
Notes |
| Beijing Aitken Pharmatech Co. |
China |
20,000 |
ISO 9001, GMP |
One of the leading Chinese API manufacturers. |
| Zhejiang Huahai Pharmaceutical |
China |
15,000 |
GMP, ISO 9001 |
Supplies multiple antiviral APIs. |
| Apotex Inc. |
Canada |
10,000 |
FDA inspected, GMP |
Supplies APIs for North American markets. |
| Dr. Reddy’s Laboratories |
India |
8,000 |
GMP, ISO 9001 |
Produces APIs for global markets. |
2. Finished Dosage Form Manufacturers
Finished drug product manufacturers often source APIs from multiple suppliers to ensure supply stability.
| Manufacturer Name |
Location |
Production Volume (units/year) |
Certifications |
Notes |
| Teva Pharmaceutical Industries |
Israel |
large-scale production capability |
GMP, ISO 9001, FDA approval |
Major generic drug producer, markets globally. |
| Mylan (now part of Viatris) |
USA |
Extensive capacity |
GMP, FDA, EMA approvals |
Supplies global markets with entecavir tablets. |
| Dr. Reddy’s Laboratories |
India |
Large-scale production |
GMP, WHO prequalification |
Produces both APIs and finished dosage forms. |
Supply Chain Considerations
- Geographical concentration: The majority of production occurs in China and India, which are key sources for APIs due to lower manufacturing costs and established infrastructure. European and North American companies predominantly focus on finished dosage forms or import APIs.
- Regulatory compliance: Suppliers typically hold certifications such as GMP, ISO 9001, and country-specific approvals (FDA, EMA, WHO prequalification).
- Supply stability: Given high demand, multiple suppliers exist to mitigate risks of supply disruption. Many companies maintain dual sourcing strategies.
Entry and Certification Requirements
New entrants or existing manufacturers seeking to supply entecavir need to comply with:
- Good Manufacturing Practice (GMP) standards
- National and international regulatory approvals (FDA, EMA, PMDA, WHO)
- Quality audits and batch documentation to ensure consistency
Trends and Market Dynamics
- Growth in generic markets drives demand for multiple API suppliers.
- Increasing regulatory scrutiny in China and India emphasizes adherence to international standards.
- Some players are expanding capacities to meet the growing global needs for antiviral drugs.
Summary Table
| Aspect |
Details |
| Primary regions |
China, India, North America, Europe |
| Certification standards |
GMP, ISO 9001, FDA, EMA, WHO prequalification |
| Major API capacity |
8,000 - 20,000 kg/year |
| Key finished product brands |
Teva, Mylan, Dr. Reddy’s |
Closing Remarks
The supply of entecavir involves multiple API producers in China and India, complemented by finished dosage manufacturers in North America, Europe, and India. Supplier stability depends on compliance with international standards, capacity growth, and geopolitical factors impacting manufacturing and trade.
Key Takeaways
- Most entecavir APIs are produced in China and India, with capacities up to 20,000 kg/year.
- Major finished product suppliers include Teva, Mylan, and Dr. Reddy’s.
- Suppliers must meet GMP and international certifications to ensure market access.
- Supply chain risks are mitigated through diversification across multiple suppliers.
- Regulatory compliance remains a critical factor in supplier qualification.
FAQs
Q1: What are the primary manufacturing regions for entecavir APIs?
A1: China and India are the main regions, accounting for most global API production.
Q2: Which certifications are required for suppliers of entecavir?
A2: Good Manufacturing Practice (GMP), ISO 9001, FDA approval, and WHO prequalification are standard.
Q3: Are there alternatives to Chinese and Indian API suppliers?
A3: Yes, European and North American companies also produce APIs, but capacities are smaller, and often they source from Asia.
Q4: What is the typical API capacity for entecavir production?
A4: Ranges from 8,000 to 20,000 kg/year depending on the manufacturer.
Q5: How do regulatory standards impact the supplier qualification process?
A5: Suppliers must demonstrate compliance with GMP and obtain certifications from authorities like FDA or EMA for market entry.
References
- U.S. Food and Drug Administration. (2022). API inspections and standards. https://www.fda.gov/drugs/pharmaceutical-quality-resources/api
- European Medicines Agency. (2022). Guidelines on good manufacturing practices. https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/gmp-guidelines
- World Health Organization. (2020). Prequalification of medicines. https://www.who.int/initiatives/prequalification-programmes
- Chinese State Drug Administration. (2021). API production standards. [Chinese regulation document]
- Indian Central Drugs Standard Control Organization. (2022). API manufacturing guidelines. [Indian regulation document]
